2 - TI Pharma
2 - TI Pharma
2 - TI Pharma
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Table 3. Mitochondrial respiration rates corrected for mitochondrial density before and during<br />
two-week treatment with placebo, prednisolone 7.5 mg or prednisolone 30 mg.<br />
Malate<br />
pmol/mg.sec.mtDNA<br />
Glutamate<br />
pmol/mg.sec.mtDNA<br />
ADP<br />
pmol/mg.sec.mtDNA<br />
Cytochrome C<br />
pmol/mg.sec.mtDNA<br />
Succinate<br />
pmol/mg.sec.mtDNA<br />
Aurovertin<br />
pmol/mg.sec.mtDNA<br />
FCCP<br />
pmol/mg.sec.mtDNA<br />
Rotenone<br />
pmol/mg.sec.mtDNA<br />
Antimycin A<br />
pmol/mg.sec.mtDNA<br />
Pre-treatment On-treatment P<br />
PLB 1.6 (1.0-3.2) 1.4 (0.6-4.2)<br />
7.5 1.4 (0.6-3.5) 1.3 (0.8-4.2)<br />
NS<br />
30 1.6 (1.0-3.7) 2.2 (1.3-5.8)<br />
PLB 2.1 (0.8-3.3) 1.8 (0.8-4.4)<br />
7.5 2.2 (1.0-3.5) 2.6 (1.1-5.9)<br />
NS<br />
30 2.2 (1.2-3.9) 2.4 (1.7-7.0)<br />
PLB 23.0 (8.3-25.5) 15.9 (6.6-25.2)<br />
7.5 17.6 (9.4-31.0) 17.1 (10.4-57.4)<br />
NS<br />
30 21.8 (12.8-38.0) 20.0 (13.4-50.5)<br />
PLB 22.2 (8.3-29.4) 16.1 (7.6-22.6)<br />
7.5 20.9 (10.0-30.0) 18.4 (10.5-58.2)<br />
NS<br />
30 21.9 (12.5-38.5) 19.2 (14.5-33.8)<br />
PLB 32.7 (12.8-41.4) 28.7 (14.8-35.2)<br />
7.5 30.7 (15.1-40.0) 27.4 (15.4-79.6)<br />
NS<br />
30 31.4 (17.7-43.6) 28.4 (21.7-54.3)<br />
PLB 7.7 (2.9-9.7) 6.8 (3.4-11.6)<br />
7.5 7.3 (3.4-12.3) 7.6 (3.6-21.8)<br />
NS<br />
30 7.6 (4.2-9.8) 8.7 (6.1-13.9)<br />
PLB 57.0 (17.7-61.3) 39.9 (17.6-74.0)<br />
7.5 44.2 (22.2-82.4) 38.8 (22.0-124.8)<br />
NS<br />
30 51.3 (30.6-66.9) 43.8 (19.5-130.0)<br />
PLB 26.3 (10.0-30.7) 22.6 (11.1-38.1)<br />
7.5 20.3 (11.2-40.0) 20.3 (12.1-71.3)<br />
NS<br />
30 25.0 (14.2-45.0) 23.0 (10.7-62.0)<br />
PLB 1.8 (0.7-3.1) 1.6 (0.6-4.9)<br />
7.5 1.8 (0.7-6.3) 1.4 (0.4-4.0)<br />
NS<br />
30 1.8 (0.4-2.9) 1.9 (0.8-4.0)<br />
Data are median (range). Between-group changes from baseline were tested by Kruskal-Wallis. No<br />
significant differences were observed between the groups. Abbreviations 7.5: prednisolone 7.5 mg; 30:<br />
prednisolone 30 mg; FCCP: carbonylcyanide-4-(trifluoromethoxy)-phenylhydrazone. PLB: placebo.<br />
Peripheral insulin sensitivity: As described previously [5], peripheral glucose uptake was<br />
non-significantly reduced by prednisolone 7.5 mg 5 (Rd= 61.05 [47.85-76.8] vs. 60 .19 [43.92-<br />
7.09] mmol/kg.min ; P= 0.090), but decreased significantly after treatment with prednisolone<br />
30 mg by 34±6% (Rd = 67.35 [50.87-93.53] vs. 42.42 [28.83-60.40]; P < 0.001).<br />
183<br />
9<br />
Chapter 9
Change language